In non–small cell lung cancer patients treated with anti-PD-1/PD-L1 antibodies, the ESPILoN score [smoking history, liver metastasis, lactate dehydrogenase (LDH), and neutrophil to lymphocyte ratio (NLR)], the Gustave Roussy Immune Score (GRIm-Score) (LDH, serum albumin (Alb), and NLR) and the RHM score (LDH, Alb, and the number of metastatic sites) was reported to be significantly correlated with prognosis14–16. The gene discussed is PDCD1; the disease is lung cancer.